Lucerastat, an iminosugar for substrate reduction therapy in Fabry Disease: Preclinical evidence - Welford, R; Mühleman, A; Priestman, D; Garzotti, M; Deymier, C; Ertel, E; Iglarz, M; Morand, O; Platt, F; Probst, M (5th Update on Fabry Nephropathy, 2017)